Company news

Erasca, Inc. news in 2026

Erasca, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Erasca to Present at Upcoming Conferences in November

November 3, 2026

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

September 10, 2026

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

September 8, 2026

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

August 24, 2026

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

August 11, 2026

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2026

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

July 13, 2026

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

July 13, 2026

Erasca to Present at the Jefferies Global Healthcare Conference

May 27, 2026

Erasca Reports First Quarter 2026 Business Updates and Financial Results

May 11, 2026

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

April 27, 2026

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

March 12, 2026

Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau

March 9, 2026

Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat

March 4, 2026

Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001

February 23, 2026

Erasca to Present at Upcoming Conferences in February

February 4, 2026

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

January 23, 2026

Erasca Announces Pricing of Upsized Public Offering of Common Stock

January 21, 2026

Erasca Announces Proposed Public Offering of $150 Million of Common Stock

January 20, 2026

Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones

January 11, 2026

Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026